October 9, 2025

New Clinical Data for Vivace Therapeutics’ Best-in-Class, Hippo Pathway-Targeting Therapy to be Presented in Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2025

Research and Publications

The Hippo Pathway and Human Cancer

Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer

June 28, 2017

Vivace Therapeutics Comes out of Stealth with $40 Million to Turn Novel Biology into First-in-Class Cancer Therapeutics